Dataset Information

PREDICTIVE FACTORS FOR PERIOPERATIVE TREATMENTS IN BLADDER CARCINOMA

ABSTRACT: Muscle-invasive bladder carcinoma (MIBC) has been classified into transcriptomic subtypes, but proteomics studies remain scarce. Fifty-eight paraffin-embedded MIBC samples obtained atransurethral resection (prior to treatment) and at the cystectomy (after neoadjuvant treatment) were analyzed for protein extraction and proteomics profiling by DIA-MS.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Bladder

DISEASE(S): Urinary Bladder Cancer

SUBMITTER: Lucia Trilla-Fuertes

LAB HEAD: Lucia Trilla-Fuertes

PROVIDER: PXD057995 | Pride | 2026-01-19

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20230630_C31988_002_S520763_6_test.raw	Raw
	20230703_C31988_002_S520758_1.raw	Raw
	20230703_C31988_003_S520759_2.raw	Raw
	20230703_C31988_004_S520760_3.raw	Raw
	20230703_C31988_005_S520761_4.raw	Raw

Items per page:

1 - 5 of 77

Publications

Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers.

Trilla-Fuertes Lucía L Pedregosa-Barbas Jorge J García-Fernández Eugenia E Zambrana Francisco F Martínez-Salas Imanol I Gajate Pablo P Becerril-Gómez Fernando F Lalanda-Delgado Pedro P Dittmann Antje A López-Vacas Rocío R Kunz Laura L Rubio Gustavo G Nieto-Torrero Sandra S Pertejo Ana A González-Peramato Pilar P Fresno Vara Juan Ángel JÁ Gámez-Pozo Angelo A Pinto-Marín Álvaro Á

International journal of molecular sciences 20260102 1

Neoadjuvant chemotherapy (NACT) is the standard treatment for muscle-invasive bladder carcinoma (MIBC), but its efficacy varies significantly among patients. The aim of this study is the identification of biomarkers and biological processes related to the response to neoadjuvant chemotherapy (NACT) in muscle-invasive bladder carcinoma (MIBC). Fifty-eight transurethral resection (TURBT) samples and thirty cystectomy samples from NACT non-responders were analyzed using mass spectrometry. Samples w ...[more]

PMID: 41516353

Similar Datasets

Project description:The Colorectal Cancer Subtyping Consortium established four Consensus Molecular Subtypes (CMS) in colorectal cancer: CMS1 (microsatellite-instability [MSI], Immune), CMS2 (Canonical, epithelial), CMS3 (Metabolic), and CMS4 (Mesenchymal). However, in the clinical practice only patients with MSI tumors have experienced a change in the management of their disease. Proteomics has experimented significant technical advances with the implementation of data-independent acquisition (DIA) as the gold-standard for the analysis of large cohort of patients, providing a dynamic framework of the disease and direct information about the effectors of the biological processes. The aim of this study is the characterization of the proteome of colon cancer CMS by DIA–based proteomics and expand the utility of CMS in the clinical practice. CMS were assigned and differences in the protein profiles between CMS were defined and evaluated using a Systems Biology approach. One hundred fifty-eight paraffin samples from colon cancer patients with stage II-III disease treated with adjuvant chemotherapy were analyzed. After applying quality criteria, 1,940 identified and quantified proteins were used for the analyses. CMS1 had an overexpression of proteins related to immune system, specifically neutrophils, phagocytosis and antimicrobial response, and a glycolytic profile. CMS3 had an overexpression of proteins related to metabolic pathways, while CMS2 showed an intermediate protein profile between CMS1-3, but with a characteristic profile regarding translation, adhesion, and mitochondria and metabolism biological processes. Two proteomics subtypes within CMS2 with different protein characteristics and prognosis were identified. CMS4 was the most different group with an overexpression of proteins related to angiogenesis, extracellular matrix, focal adhesion, and complement activation. In conclusion, DIA LC-MS/MS proteomics characterization of CRC CMS established new features for each CMS, such as a higher mitochondrial activity in CMS2 or an overexpression of proteins related to phagocytosis in CMS1, but also confirmed previous findings established using transcriptomics such as an overexpression of proteins related to angiogenesis in CMS4. In this CMS4 subtype, several adhesion-related proteins suggested a high metastatic profile and a possible chemoresistance that may explain the worse prognosis of this subtype. CMS1 was characterized as immune and glycolitic-active subtype, being the combination of immunotherapy and glycolytic inhibitors a possible therapeutic strategy. Additionally, two different CMS2 proteomics-based subtypes with different prognosis and possible therapeutic targets were identified. These proccesses could be used as therapeutic targets in the future.